Cellceutix Corp. (CTIX.OB) Making Progress with New Autism Treatment Compound
Cellceutix Corp. today issued a press release to announce that they are seeing progress with their compound KM-391 in the treatment of autism. Autism, which affects millions of people annually and is one of the fastest growing diseases in the world, does not have any treatments that address the root causes at this point. Cellceutix is the first company moving forward with progress to address this disease at its core. To quote the Cellceutix website: “Preliminary testing of KM-391 in mice revealed that the test animals showed a significant increase in serotonin uptake compared to controls, with no apparent side-effects…